Brian Frenzel has spent the past two decades as a private investor and management advisor with AnVent Enterprises, a private investment and advisory services provider located in Mountain View, California. In this role, Brian Frenzel provides funding and advising to early stage biomedical product companies, including those furthering the ongoing war against cancer. He also serves as CEO of cancer drug discovery company, Tosk, Inc. Cancer is one of the deadliest diseases known to mankind, with over 600,000 cancer deaths occurring every year in the United States. However, reports from the American Cancer Society state that the cancer death rate in the United States fell 2.2 percent from 2016 to 2017, the largest year-to-year drop-off ever recorded. Dating back to 1991, the cancer death rate among Americans has fallen nearly 30 percent, accounting for approximately 2.9 million lives saved over that timeframe. The online report was headed by American Cancer Society director of surveillance research Rebecca Siegel, and published in “CA: A Cancer Journal for Clinicians”. Dr. Spiegel stated that any impact made on the cancer mortality rate is a victory, particularly such a historic drop off. Various factors were cited to explain the decrease in mortality, ranging from advances in treatment for lung cancer, one of the deadliest forms of the disease, to reduced smoking rates among Americans.
0 Comments
Leave a Reply. |
AuthorAt Genelabs Technologies in the 1980’s, Brian Frenzel served on the front lines in the war on HIV/AIDS and championed projects to identify and diagnose new hepatitis viruses. Archives
June 2020
Categories
All
|